Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB^3™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2022. All are available under the Company’s profile on SEDAR and on the Company’s website at www.bioasis.us/investors/.